Henry Schein Reaffirms 2026 Profit Target, but Execution Risks Keep Us on the Sidelines

What happened

Henry Schein executives reiterated confidence in their 2026 commitments, pointing to steady U.S. dental demand and a planned $125 million profit lift. While the announcement supports the post-cyber recovery narrative, the DeepValue report flags that the stock trades at a ~6% premium to a conservative DCF estimate, offering little margin of safety. The company still faces material execution risks from ongoing restructuring charges through 2027, lingering IT vulnerabilities, a major leadership transition, and leverage near 3x EBITDA. The BOLD+1 strategy and mix shift toward higher-margin specialty and technology are positives, but the risk-reward remains balanced and not compelling enough for an outright buy. We maintain our WAIT stance until clearer evidence of durable margin expansion and free cash flow improvement emerges.

Implication

Long-term investors should monitor margin trajectory, cyber remediation, and restructuring progress. A pullback toward the DCF anchor (~$71) or sustained margin improvement could turn the thesis more favorable.

Thesis delta

The news of steady dental demand and a $125M profit lift by 2026 provides modest support to the recovery case but does not materially alter the risk-reward calculus. The DeepValue report's WAIT judgment remains appropriate given the still-precarious execution path and premium valuation. We see no shift in the thesis—execution momentum must be demonstrated in actual earnings reports, not just management guidance.